REFERENCES
- Craig R. J. Urine Screening for Drugs and Trazodone. [Letter] Br. J. Psychiatry 1996; 169: 669–670
- Marek G. J., McDougle C. J., Price L. H., Seiden L. S. A Comparison of Trazodone and Fluoxetine: Implications for a Serotonergic Mechanism of Antidepressant. Psychopharmacology 1992; 109: 2–11
- Caccia S., Ballabio M., Samanin R., Zanini M. G., Garattini S. (-)m-Chlorophenyl-Piperazine, a Central 5-Hydroxytryptamine Agonist, Is a Metabolite of Trazodone. J.Pharm. Pharmacol. 1981; 33: 477–478
- Moore F. M.L., Jarvie D. R., Simpson D. Comparison of Polyclonal and Monoclonal Tests for Routine Screening of Urine for Amphetamines. Ann. Clin. Biochem. 1996; 33: 78–81
- Olsen K. M., Gulliksen M., Christopherson A. A. Metabolites of Chlorpromazine and Brompheniramine May Cause False-Positive Urine Amphetamine Results with Monoclonal MIT d.a.u. Immunoassay. [Letter] Clin. Chem. 1992; 38: 611–612
- Crane T., Dawson C. M., Tickner T. R. False-Positive Results from the Syva EMITTM d.a.u. Monoclonal Amphetamine Assay as a Result of Antipyschotic Drug Therapy. [Letter] Clin. Chem. 1993; 39: 549
- Schmolke M., Hallbach J., Guder W. G. False-Positive Results for Urine Amphetamine and Opiate Immunoassays in a Patient Intoxicated with Perazine. [Letter] Clin. Chem. 1996; 42: 1725–1726
- Triage® Drugs of Abuse Panel Plus TCA. Product Information Brochure. Biosite Diagnostics, San Diego, CA 1996
- Ellenhorn M. J., Barceloux D. G. Medical Toxicology. Diagnosis and Treatment of Human Poisoning. Elsevier, New York 1988; 409